Latest News

Gilead to stop late-stage study of Covid-19 treatment


A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

David Paul Morris | Bloomberg | Getty Images

Gilead Sciences said on Monday it had decided to stop a late-stage trial of its intravenous treatment, Veklury, in high-risk non-hospitalized patients with Covid-19.

The company said it no longer believes that developing a multiple-day injection that requires administration in a healthcare setting addresses an unmet need for non-hospitalized patients.

The decision to stop the study is not due to efficacy or safety concerns, Gilead said.

Cannabis company Aphria said it may seek other consumer deals as it waits for U.S. pot legalization

Previous article

Morgan Stanley picks 5 China stocks with big upside — and big dividends too

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News